Response to: Letter to the Editor with Regard to the Cost-Effectiveness of Hybrid Closed-Loop Systems Versus Multiple Daily Injections Plus Intermittently Scanned Continuous Glucose Monitoring in Type 1 Diabetes in the Netherlands

Note: Funding Information: Funding for this response letter was provided by Medtronic International Trading Sàrl. Medical writing and editorial support for the response letter was provided by Richard Pollock at Covalence Research Ltd. All authors contributed to the response letter. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. Erik H Serné is an employee of Amsterdam UMC. Stéphane Roze is an employee of Vyoo Agency. Maria Ida Buompensiere and Simona De Portu are employees of Medtronic International Trading Sàrl. William Valentine is a director and employee of Ossian Health Economics and Communications GmbH, which received consulting fees to support preparation of the cost-effectiveness manuscript. Harold W de Valk is an employee of University Medical Center, Utrecht. This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. Funding Information: Funding for this response letter was provided by Medtronic International Trading Sàrl.